Comparative Pharmacology
Head-to-head clinical analysis: CARBOCAINE versus LIDOCAINE HYDROCHLORIDE W EPINEPHRINE.
Head-to-head clinical analysis: CARBOCAINE versus LIDOCAINE HYDROCHLORIDE W EPINEPHRINE.
CARBOCAINE vs LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepivacaine, the active ingredient in Carbocaine, is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses.
Lidocaine is a sodium channel blocker that inhibits voltage-gated sodium channels, preventing depolarization and conduction of nerve impulses. Epinephrine is an alpha- and beta-adrenergic agonist that causes vasoconstriction, reducing systemic absorption of lidocaine and prolonging local anesthetic effect.
1% to 2% solution, 5-20 mL local infiltration or nerve block; maximum dose 400 mg (or 7 mg/kg) per 90-minute period.
Local anesthesia: 1-5 mL of 1% or 2% solution with epinephrine 1:100,000 or 1:200,000; maximum dose 7 mg/kg lidocaine (500 mg without epinephrine, 7 mg/kg with epinephrine) per procedure. Intravenous: 1-1.5 mg/kg bolus for ventricular arrhythmias, followed by continuous infusion 1-4 mg/min.
None Documented
None Documented
2.0–3.5 hours in adults; prolonged in patients with hepatic impairment (up to 8–10 hours) or renal dysfunction.
Terminal half-life 1.5-2 hours (single dose), prolonged to 2-3 hours with continuous infusion; in heart failure or hepatic cirrhosis, half-life may exceed 5 hours.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination, with less than 5% excreted in feces via biliary elimination.
Renal: unchanged drug <10%, major metabolites (MEGX and GX) ~70% renal; biliary: <10% fecal; total clearance ~10-20 mL/min/kg. Renal impairment prolongs elimination of metabolites.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)